In two independent treatment studies in AD patients (one with encapsulated NGF-releasing cells and the other with a ChEI), we showed that CSF ChAT levels increased in response to the treatment and that the increase was positively correlated with measures of cognition (Karami et al., 2015, 2019). The gene discussed is NGF; the disease is Alzheimer disease.